The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery

References

• Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol. 2021;74(5):1212–1224. doi:10.1016/j.jhep.2021.01.035
   PubMed Web of Science ®Google Scholar
• Leoni S, Sansone V, Lorenzo S, et al. Treatment of combined hepatocellular and cholangiocarcinoma. Cancers. 2020;12(4):794. doi:10.3390/cancers12040794
   PubMed Web of Science ®Google Scholar
• Schizas D, Mastoraki A, Routsi E, et al. Combined hepatocellular-cholangiocarcinoma: an update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int. 2020;19(6):515–523. doi:10.1016/j.hbpd.2020.07.004
   PubMed Web of Science ®Google Scholar
• Kim TH, Kim H, Joo I, Lee JM. Combined hepatocellular-cholangiocarcinoma: changes in the 2019 World Health Organization histological classification system and potential impact on imaging-based diagnosis. Korean J Radiol. 2020;21(10):1115–1125. doi:10.3348/kjr.2020.0091
   PubMed Web of Science ®Google Scholar
• Sempokuya T, Wien EA, Pattison RJ, Ma J, Wong LL. Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma. World J Hepatol. 2020;12(11):1020–1030. doi:10.4254/wjh.v12.i11.1020
   PubMed Web of Science ®Google Scholar
• Yamashita YI, Aishima S, Nakao Y, et al. Clinicopathological characteristics of combined hepatocellular cholangiocarcinoma from the viewpoint of patient prognosis after hepatic resection: high rate of early recurrence and its predictors. Hepatol Res. 2020;50(7):863–870. doi:10.1111/hepr.13507
   PubMed Web of Science ®Google Scholar
• Fang Q, Chen H. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma. Mol Med. 2020;26(1):60. doi:10.1186/s10020-020-00185-z
   PubMed Web of Science ®Google Scholar
• Sartoris R, Gregory J, Dioguardi BM, Ronot M, Vilgrain V. HCC advances in diagnosis and prognosis: digital and Imaging. Liver Int. 2021;41(Suppl 1):73–77. doi:10.1111/liv.14865
   PubMed Web of Science ®Google Scholar
• Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells. 2020;9(6):1370. doi:10.3390/cells9061370
   PubMed Web of Science ®Google Scholar
• Gao YX, Yang TW, Yin JM, et al. Progress and prospects of biomarkers in primary liver cancer (Review). Int J Oncol. 2020;57(1):54–66. doi:10.3892/ijo.2020.5035
   PubMed Web of Science ®Google Scholar
• Zhang XF, Xue F, Dong DH, et al. Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis. Ann Surg. 2021;274(6):e1187–e1195. doi:10.1097/SLA.0000000000003788
   PubMed Web of Science ®Google Scholar
• Matsukuma KE, Yeh MM. Update on the pathology of liver neoplasms. Ann Diagn Pathol. 2019;38:126–137. doi:10.1016/j.anndiagpath.2018.10.005
   PubMed Web of Science ®Google Scholar
• Kim M, Hwang S, Ahn C-S, et al. Postresection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma according to the 2010 World Health Organization classification: single-center experience of 168 patients. Ann Surg Treat Res. 2021;100(5):260–269. doi:10.4174/astr.2021.100.5.260
   PubMed Web of Science ®Google Scholar
• Kim M, Hwang S, Ahn CS, et al. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification. Asian J Surg. 2021;44(11):1389–1395. doi:10.1016/j.asjsur.2021.03.002
   PubMed Web of Science ®Google Scholar
• Wang G, Wang Q, Liang N, et al. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer. Cell Death Dis. 2020;11(5):313. doi:10.1038/s41419-020-2509-x
   PubMed Web of Science ®Google Scholar
• Luo D, Zhao D, Zhang M, et al. Alternative splicing-based differences between hepatocellular carcinoma and intrahepatic cholangiocarcinoma: genes, immune microenvironment, and survival prognosis. Front Oncol. 2021;11:731993. doi:10.3389/fonc.2021.731993
   PubMed Web of Science ®Google Scholar
• Mandaliya H, Jones M, Oldmeadow C, Nordman II. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8(6):886–894. doi:10.21037/tlcr.2019.11.16
   PubMed Web of Science ®Google Scholar
• Qin B, Ma N, Tang Q, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol. 2016;26(3):372–376. doi:10.3109/14397595.2015.1091136
   PubMed Web of Science ®Google Scholar
• Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–181. doi:10.1016/j.lungcan.2017.07.024
   PubMed Web of Science ®Google Scholar
• Erre GL, Paliogiannis P, Castagna F, et al. Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis. Eur J Clin Invest. 2019;49(1):e13037. doi:10.1111/eci.13037
   PubMed Web of Science ®Google Scholar
• Liu H, Qiu G, Hu F, Wu H. Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection. World J Surg Oncol. 2021;19(1):218. doi:10.1186/s12957-021-02330-2
   PubMed Web of Science ®Google Scholar
• Xu Q, Yan Y, Gu S, et al. A novel inflammation-based prognostic score: the fibrinogen/albumin ratio predicts prognoses of patients after curative resection for hepatocellular carcinoma. J Immunol Res. 2018;2018:1–11. doi:10.1155/2018/4925498
   Web of Science ®Google Scholar
• Ishii T, Ito T, Sumiyoshi S, et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World J Surg Oncol. 2020;18(1):319. doi:10.1186/s12957-020-02099-w
   PubMed Web of Science ®Google Scholar
• Deng S, Fan Z, Xia H, et al. Fibrinogen/Albumin ratio as a promising marker for predicting survival in pancreatic neuroendocrine neoplasms. Cancer Manag Res. 2021;13:107–115. doi:10.2147/CMAR.S275173
   PubMed Web of Science ®Google Scholar
• Xue R, Chen L, Zhang C, et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell. 2019;35(6):932–947. doi:10.1016/j.ccell.2019.04.007
   PubMed Web of Science ®Google Scholar
• Liu WR, Tian MX, Tao CY, et al. Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. BMC Cancer. 2020;20(1):642. doi:10.1186/s12885-020-07138-z
   PubMed Web of Science ®Google Scholar
• Wang T, Yang X, Tang H, et al. Integrated nomograms to predict overall survival and recurrence-free survival in patients with combined hepatocellular cholangiocarcinoma (cHCC) after liver resection. Aging. 2020;12(15):15334–15358. doi:10.18632/aging.103577
   PubMedGoogle Scholar
• Xue GQ, Li CP, Lv A, et al. Predictive value of preoperative controlling nutritional status score combined with Fibrinogen-Albumin ratio in postoperative local recurrence-free survival of patients with retroperitoneal liposarcoma. Cancer Manag Res. 2021;13:6157–6167. doi:10.2147/CMAR.S307920
   PubMed Web of Science ®Google Scholar
• Gao W, Li M, Zhang Y. Fibrinogen/Albumin ratio (FAR) in patients with triple negative breast cancer and its relationship with epidermal growth factor receptor expression. Onco Targets Ther. 2021;14:5403–5415. doi:10.2147/OTT.S339973
   PubMed Web of Science ®Google Scholar
• Chen J, Hao L, Zhang S, et al. Preoperative Fibrinogen-Albumin ratio, potential prognostic factors for bladder cancer patients undergoing radical cystectomy: a two-center study. Cancer Manag Res. 2021;13:3181–3192. doi:10.2147/CMAR.S300574
   PubMed Web of Science ®Google Scholar
• Guo Z, Liang J. Fibrinogen-Albumin ratio index (FARI) as a certain prognostic biomarker in pretreated patients with immunotherapy. Cancer Manag Res. 2021;13:4169–4180. doi:10.2147/CMAR.S307272
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou CW, Zhu GQ, et al. A multidimensional nomogram combining imaging features and clinical factors to predict the invasiveness and metastasis of combined hepatocellular cholangiocarcinoma. Ann Transl Med. 2021;9(20):1518. doi:10.21037/atm-21-2500
   PubMed Web of Science ®Google Scholar
• Zhou C, Wang Y, Ma L, Qian X, Yang C, Zeng M. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol. 2022;32(1):78–88. doi:10.1007/s00330-021-08188-y
   PubMed Web of Science ®Google Scholar